Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary

Xilio Therapeutics (Nasdaq: XLO) will present new preclinical data for its masked T cell engager program targeting CLDN18.2 at the AACR Annual Meeting, April 17-22, 2026 in San Diego.

The poster, titled Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager, is scheduled for Monday, April 20, 2026, 9:00 a.m.–12:00 p.m. PST at Poster Section 10, Poster Board 11 (Abstract No. 1619).

Key Figures

AACR meeting dates: April 17-22, 2026 Poster session date: April 20, 2026 Session time: 9:00 a.m.–12:00 p.m. PST +3 more

6 metrics

AACR meeting dates April 17-22, 2026 American Association for Cancer Research Annual Meeting

Poster session date April 20, 2026 XTX601 poster session date at AACR

Session time 9:00 a.m.–12:00 p.m. PST AACR poster session window for XTX601

Poster section Section 10 Location of XTX601 poster at AACR

Poster board Board 11 Assigned poster board for XTX601

Abstract number 1619 AACR abstract identifier for XTX601 data

Market Reality Check

Price: $7.43 Vol: Volume 53,512 is 1.49x th...

normal vol

$7.43 Last Close

Volume Volume 53,512 is 1.49x the 20-day average of 35,990 shares. normal

Technical Shares at $7.43 are trading below the 200-day MA of $9.72 and 55.02% under the 52-week high.

Peers on Argus

XLO gained 7.26% while close peers were mixed: MRSN (+0.62%), JSPR (+2.46%), LVT...

1 Up 1 Down

XLO gained 7.26% while close peers were mixed: MRSN (+0.62%), JSPR (+2.46%), LVTX (-3.87%), BCAB (-3.78%), MURA (flat). Momentum scanner only flagged two other names with opposing directions, supporting a stock-specific move.

Historical Context

5 past events · Latest: Mar 12 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Reverse stock split	Negative	-5.3%	Announced 1-for-14 reverse split to support Nasdaq bid-price compliance.
Mar 02	Conference participation	Neutral	+2.4%	Planned fireside chat at Leerink Partners Global Healthcare Conference.
Mar 02	Inducement grants	Neutral	+2.4%	Granted 50,050 stock options to new employees under inducement plan.
Feb 11	Equity financing	Neutral	+11.4%	Priced pre-funded warrant offering for expected gross proceeds of $40M.
Jan 08	Corporate update	Positive	+2.6%	Reported $137.5M cash, extended runway, and CLDN18.2 T cell engager milestone.

Pattern Detected

Recent news, including financings and corporate actions, has typically seen price moves that align directionally with the perceived tone of the announcement.

Recent Company History

Over the last few months, Xilio has focused on strengthening its balance sheet and maintaining its listing, alongside pipeline progress. An underwritten pre-funded warrant offering in February 2026 coincided with an 11.44% gain, while a later 1-for-14 reverse split on March 12, 2026 saw a -5.31% move. Earlier updates highlighted cash of $137.5M and extended runway, as well as conference participation and inducement grants. Today’s AACR preclinical poster fits into this ongoing narrative of pipeline visibility and scientific outreach.

Market Pulse Summary

This announcement highlights new preclinical data for Xilio’s masked CLDN18.2-targeting T cell engag...

Analysis

This announcement highlights new preclinical data for Xilio’s masked CLDN18.2-targeting T cell engager XTX601, to be presented at AACR in April 2026. It reinforces earlier disclosures that emphasized a broad immuno-oncology pipeline and collaboration-driven programs. In context of recent financings, a reverse split, and extended cash runway, investors may watch for how such preclinical updates translate into clinical milestones, regulatory interactions, and partnership traction over time.

Key Terms

t cell engager, cldn18.2, immuno-oncology

3 terms

t cell engager medical

"Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager"

A T cell engager is an engineered protein drug that physically links a patient’s T cell — the immune system’s attack cell — to a diseased cell so the T cell will recognize and kill it. For investors it matters because clinical trial results, manufacturing success and safety profiles determine whether the therapy becomes a widely adopted, high-value treatment or a costly failure; think of it like a matchmaker that must reliably bring soldiers to the right target without triggering friendly fire.

cldn18.2 medical

"masked T cell engager targeting <b>CLDN18.2</b>"

Cldn18.2 is a specific form of a protein that normally helps hold stomach cells together and, when present on the surface of cancer cells, acts as a visible marker for targeted treatments. Investors should care because drugs and tests that recognize cldn18.2 can selectively find and attack tumors—like a lock-and-key system—making it a focal point for developing therapies, clinical trials, and companion diagnostics that can drive revenue and valuation.

immuno-oncology medical

"developing masked immuno-oncology therapies for people living with cancer"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California.

Poster presentation details, as follows:

Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager
Session Category: Immunology
Session Title: T Cell Engagers 1
Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:00 p.m. PST
Location: Poster Section 10
Poster Board: 11
Abstract Number: 1619

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting www.xiliotx.com and follow us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to present data related to Xilio’s masked T cell engager program targeting CLDN18.2. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; and Xilio’s ability to maintain its collaboration or partnership agreements with AbbVie, Gilead and Roche. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the SEC, including Xilio’s most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Investor Contact
Alex Lobo, Precision AQ
alex.lobo@precisionaq.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

FAQ

When will Xilio Therapeutics (XLO) present its XTX601 poster at AACR 2026?

Xilio will present on Monday, April 20, 2026, from 9:00 a.m. to 12:00 p.m. PST. According to the company, the poster session will be in Poster Section 10 at Poster Board 11 (Abstract No. 1619).

What preclinical data will Xilio (XLO) present about XTX601 at AACR 2026?

Xilio will present new preclinical results for XTX601, a masked Claudin 18.2-targeting T cell engager. According to the company, the poster covers discovery and optimization work supporting the program.

Where can investors find Xilio's (XLO) AACR poster details and abstract number?

The poster is listed as Abstract No. 1619 at Poster Section 10, Poster Board 11. According to the company, attendees can view the poster during the T Cell Engagers 1 session on April 20, 2026.

Is Xilio's XTX601 data clinical or preclinical in the AACR 2026 presentation?

The presentation is explicitly described as preclinical data for XTX601. According to the company, the poster focuses on discovery and optimization rather than clinical trial readouts.

What session will Xilio (XLO) appear in at the AACR Annual Meeting 2026?

Xilio's poster appears in the Immunology track within the T Cell Engagers 1 session. According to the company, the poster presentation is scheduled for April 20, 2026, during the morning poster session.